Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 1, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 3, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001682852-26-000044
Filed / recorded
Mar 3, 2026, 9:19 PM UTC
Added to OQRO
Oct 2, 2026, 12:28 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
Moderna, Inc.
Issuer CIK
1682852
Ticker
MRNA
Reporting person
Stephane Bancel
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Mar 1, 2026
Transaction code
A
Shares / units
250,932
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
250,932
Ownership form
Direct
Amendment
No
Footnotes from the filing
25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.